These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7220158)

  • 21. [The echocardiographic characteristics of cardiac lesions in beta-thalassemia].
    Musaev SK; Babaev AA; Dadasheva TS; Nasonova VA
    Revmatologiia (Mosk); 1990; (2):11-7. PubMed ID: 2218258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta thalassemia and heart disease: three decades of gradual progress.
    Engle MA; Ehlers KH; O'Loughlin JE; Giardina PJ; Hilgartner MW
    Trans Am Clin Climatol Assoc; 1985; 96():24-33. PubMed ID: 6242259
    [No Abstract]   [Full Text] [Related]  

  • 23. The cardiac manifestations of thalassemia major: natural history, noninvasive cardiac diagnostic studies and results of cardiac catheterization.
    Ehlers KH; Levin AR; Klein AA; Markenson AL; O'Loughlin JE; Engle MA
    Cardiovasc Clin; 1981; 11(2):171-86. PubMed ID: 7214380
    [No Abstract]   [Full Text] [Related]  

  • 24. Intensive transfusion therapy in thalassemia major.
    Beard ME; Necheles TF; Allen DM
    Pediatrics; 1967 Nov; 40(5):911-5. PubMed ID: 6075668
    [No Abstract]   [Full Text] [Related]  

  • 25. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
    Chang HH; Lu MY; Peng SS; Yang YL; Lin DT; Jou ST; Lin KH
    Ann Hematol; 2015 Dec; 94(12):1945-52. PubMed ID: 26404899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 27. Thalassemia: the continued challenge.
    Nathan DG
    Ann N Y Acad Sci; 2005; 1054():1-10. PubMed ID: 16339645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI and iron-overload cardiomyopathy in thalassaemia.
    Pennell D
    Circulation; 2006 Mar; 113(11):f43-4. PubMed ID: 16552847
    [No Abstract]   [Full Text] [Related]  

  • 29. Adherence to deferoxamine therapy: heeding Hippocrates and Osler.
    Olivieri NF
    Am J Hematol; 2004 Aug; 76(4):415-6. PubMed ID: 15282681
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of cardiac function in patients with thalassemia major.
    Nienhuis AW; Griffith P; Strawczynski H; Henry W; Borer J; Leon M; Anderson WF
    Ann N Y Acad Sci; 1980; 344():384-96. PubMed ID: 6930878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infections and Cooley disease.
    Schiliro G; Romeo MA; Di Gregorio F; Sciacca A; Musumeci S; Russo G
    Birth Defects Orig Artic Ser; 1987; 23(5A):487-93. PubMed ID: 3318951
    [No Abstract]   [Full Text] [Related]  

  • 32. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 33. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal study of cardiac function in thalassemia major.
    Ehlers KH; Levin AR; Markenson AL; Marcus JR; Klein AA; Hilgartner MW; Engle MA
    Ann N Y Acad Sci; 1980; 344():397-404. PubMed ID: 6930879
    [No Abstract]   [Full Text] [Related]  

  • 37. Physiology and pathophysiology of iron cardiomyopathy in thalassemia.
    Wood JC; Enriquez C; Ghugre N; Otto-Duessel M; Aguilar M; Nelson MD; Moats R; Coates TD
    Ann N Y Acad Sci; 2005; 1054():386-95. PubMed ID: 16339687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
    Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
    Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Better survival and less cardiac morbidity in female patients with thalassemia major: a review of the literature.
    Marsella M; Pepe A; Borgna-Pignatti C
    Ann N Y Acad Sci; 2010 Aug; 1202():129-33. PubMed ID: 20712783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.